Protein News and Research

RSS

Proteins are complex molecules that are made up of amino acids. They can be found in every cell in the body, and carry out vital processes that keep human beings alive. Mutations in proteins can lead to a multitude of diseases, the most common being cancer.

Multiple clinical study results of ABRAXANE to be presented by Abraxis BioScience

Abraxis BioScience, Inc., a fully integrated biotechnology company, today announced that multiple clinical studies of the chemotherapy agent ABRAXANE® for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) will be presented at the 32nd Annual San Antonio Breast Cancer Symposium (SABCS), being held in San Antonio, Texas from December 9 to December 13.

9 Dec 2009

Most antidepressant medications raise serotonin levels and miss key target of clinical depression

A key brain protein called monoamine oxidase A (MAO-A) - is highly elevated during clinical depression yet is unaffected by treatment with commonly used antidepressants, according to an important study published today in the Archives of General Psychiatry. The study has important implications for our understanding of why antidepressants don't always work.

9 Dec 2009

Multi-institutional study identifies potential treatment target for ovarian cancer

A multi-institutional study has identified a potential personalized treatment target for the most common form of ovarian cancer. In the December 8 issue of Cancer Cell, the research team describes finding that a gene called MAGP2 - not previously associated with any type of cancer - was overexpressed in papillary serous ovarian tumors of patients who died more quickly. They also found evidence suggesting possible mechanisms by which MAGP2 may promote tumor growth.

9 Dec 2009

Bird influenza viruses have a variety of strategies to cross the species barrier

The 2009 H1N1 influenza virus used a new strategy to cross from birds into humans, a warning that it has more than one trick up its sleeve to jump the species barrier and become virulent.

9 Dec 2009

Soy food associated with lower risk of death and breast cancer recurrence, says new study

Researchers at Vanderbilt-Ingram Cancer Center, led by Xiao Ou Shu, M.D., Ph.D., professor of Medicine, have found that a higher intake of soy foods was associated with a lower risk of death and breast cancer recurrence among breast cancer patients in China. The study is published in the December 9 issue of JAMA.

9 Dec 2009

Epizyme closes Series B financing to a total of $40 million

Epizyme, Inc., a biopharmaceutical company translating key discoveries in the field of epigenetics into novel pharmaceutical agents, announced today the participation of New Enterprise Associates (NEA) in its Series B, bringing the total financing to $40M.

9 Dec 2009

Neuroscientists suggest risky therapy for aging brain may be avoidable by focusing on hormone target

Estrogen seems to act like a middleman in its positive effect on the brain, raising the possibility that future drugs may bypass the carcinogenic hormone altogether while reaping its benefits.

8 Dec 2009

Combination of gene and cell therapy improves critical limb ischemia associated with aging or diabetes

Blood vessel blockage, a common condition in old age or diabetes, leads to low blood flow and results in low oxygen, which can kill cells and tissues. Such blockages can require amputation resulting in loss of limbs. Now, using mice as their model, researchers at Johns Hopkins have developed therapies that increase blood flow, improve movement and decrease tissue death and the need for amputation.

8 Dec 2009

Scientists identify new potential drug for treating acute myeloid leukaemia

EUREKA project E! 3172 NKSTIM has produced a new potential drug to stimulate cancer patients' own 'natural killer' cells to attack and eliminate cancer cells; currently undergoing clinical testing in patients with leukaemia or myeloma.

8 Dec 2009

MCG receives $1.8M stimulus grant

It's a $1.8 million shot in the arm to the largest grant the Medical College of Georgia has ever received.

8 Dec 2009

Eidogen-Sertanty licenses its TIP technology for FDA's National Center for Toxicological Research

Eidogen-Sertanty, Inc., a San Diego-based computational drug discovery solutions provider, announced today they have licensed their Target Informatics Platform (TIP) to the U.S. Food and Drug Administration's National Center for Toxicological Research (NCTR).

8 Dec 2009

ASH meeting highlights H1N1 pandemic threat, new trends and treatment options for children with genetic blood disorder

Sickle cell disease, a condition characterized by deformed and dysfunctional red blood cells, is one of the most common genetic blood disorders affecting millions of people around the world, including more than 70,000 Americans (National Heart, Lung, and Blood Institute.

8 Dec 2009

Tranzyme Pharma and Bristol-Myers Squibb sign collaboration agreement

Tranzyme Pharma today announced that it has entered into a strategic collaboration agreement with Bristol-Myers Squibb Company to discover, develop and commercialize novel macrocyclic compounds directed against targets of interest to Bristol-Myers Squibb.

8 Dec 2009

CML patients on nilotinib or dasatinib drug achieve better response than imatinib drug

Two medications approved as treatment for drug-resistant chronic myeloid leukemia continue to provide patients with quicker, better responses as a first treatment than the existing front-line drug, researchers at The University of Texas M. D. Anderson Cancer Center reported at the 51st Annual Meeting of the American Society of Hematology.

8 Dec 2009

Positive data from ARIAD Pharmaceuticals' ongoing AP24534 study in advanced hematological cancer patients

ARIAD Pharmaceuticals, Inc. today announced positive clinical data from an ongoing Phase 1 study of its investigational, pan-BCR-ABL inhibitor, AP24534, in patients with advanced hematological cancers.

8 Dec 2009

Discovery may lead to new treatments for late-stage breast cancer

Researchers from the Indiana University School of Medicine and colleagues at the University of Texas Southwestern and Case Western University have determined how the protein Mdm2, which is elevated in late-stage cancers, disables genes that suppress the growth of tumors. The finding may lead to the development of new drugs for late stage breast cancer and other difficult to treat malignancies.

8 Dec 2009

New genetic approach may hold promise for sickle cell disease

A new genetic approach to treating sickle cell disease is showing promising results in mice, report researchers from Children's Hospital Boston. By inactivating a gene they previously discovered to be important in the laboratory, they were able to boost production of a healthy fetal form of hemoglobin in the mice, potentially compensating for the defective adult hemoglobin that causes red blood cells to "sickle" and obstruct blood flow.

8 Dec 2009

ImmunoGen's SAR3419 holds hope for B-cell non-Hodgkin’s lymphoma

ImmunoGen, Inc., a biopharmaceutical company that develops targeted anticancer therapeutics, today announced the presentation of encouraging initial clinical findings with SAR3419 at the American Society of Hematology (ASH) 51st Annual Meeting and Exposition. Among the findings reported were responses to SAR3419 – administered as a single agent – among patients with B-cell non-Hodgkin's lymphoma that is refractory to treatment with rituximab (Rituxan®).

8 Dec 2009

New research discovers link between HIV-related cognitive deficits and Alzheimer's-related dementia

More than half of HIV patients experience memory problems and other cognitive impairments as they age, and doctors know little about the underlying causes. New research from Washington University School of Medicine in St. Louis suggests HIV-related cognitive deficits share a common link with Alzheimer's-related dementia: low levels of the protein amyloid beta in the spinal fluid.

8 Dec 2009

Phase II clinical trial results reveal positive effects of omacetaxine against CML

Results from a phase II clinical trial indicate a novel drug may provide a treatment option for chronic myeloid leukemia (CML) patients who do not respond to current therapies, researchers from The University of Texas M. D. Anderson Cancer Center report today at the 51st Annual Meeting of the American Society of Hematology.

8 Dec 2009

Protein News and Research

Further Reading

Multiple clinical study results of ABRAXANE to be presented by Abraxis BioScience

Most antidepressant medications raise serotonin levels and miss key target of clinical depression

Multi-institutional study identifies potential treatment target for ovarian cancer

Bird influenza viruses have a variety of strategies to cross the species barrier

Soy food associated with lower risk of death and breast cancer recurrence, says new study

Epizyme closes Series B financing to a total of $40 million

Neuroscientists suggest risky therapy for aging brain may be avoidable by focusing on hormone target

Combination of gene and cell therapy improves critical limb ischemia associated with aging or diabetes

Scientists identify new potential drug for treating acute myeloid leukaemia

MCG receives $1.8M stimulus grant

Eidogen-Sertanty licenses its TIP technology for FDA's National Center for Toxicological Research

ASH meeting highlights H1N1 pandemic threat, new trends and treatment options for children with genetic blood disorder

Tranzyme Pharma and Bristol-Myers Squibb sign collaboration agreement

CML patients on nilotinib or dasatinib drug achieve better response than imatinib drug

Positive data from ARIAD Pharmaceuticals' ongoing AP24534 study in advanced hematological cancer patients

Discovery may lead to new treatments for late-stage breast cancer

New genetic approach may hold promise for sickle cell disease

ImmunoGen's SAR3419 holds hope for B-cell non-Hodgkin’s lymphoma

New research discovers link between HIV-related cognitive deficits and Alzheimer's-related dementia

Phase II clinical trial results reveal positive effects of omacetaxine against CML

Revolutionizing Life Science: An Interview with SCIEX on ASMS, the SCIEX 7500+ System, and AI-Driven Quantitation

From Discovery Biology to ELRIG Chair

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Latest Life Science News